Intelligent Bio Solutions
NEW YORK, New York · Health Care, Medical
Intelligent Bio Solutions is on a mission to redefine the approach to testing and deliver pain-free, accessible solutions that drive transformative change and improve the quality of life.
Key facts
- Headquarters
- NEW YORK, New York
- Employees
- 51
- Industries
- Health Care, Medical
- Status
- Public (INBS)
- Website
- ibs.inc
- Company page
Recent activity at Intelligent Bio Solutions
- : SEC 8-K (7.01): The filing relates to a Regulation FD Disclosure by Intelligent Bio Solutions Inc, where they provided a presentation to investors on October 13, 2026. The presentation covers key aspects of the Company's business and operations, offering insights to stakeholders. Interested parties can access this presentation through the Company's Investors section on their website. The disclosure is intended to inform investors without being considered 'filed' under the Securities Exchange Act.
- : SEC 8-K (8.01): On September 10, 2026, Intelligent Bio Solutions Inc. reported updates to its shares outstanding in accordance with Item 8.01, Other Events. This update includes the exercise of previously disclosed prefunded warrants for the purchase of 285,000 shares of common stock and the issuance of 4,333 shares of restricted common stock pursuant to an Investor Relations and Corporate Development Advisory Agreement effective February 29, 2024. Following these transactions, the total number of outstanding shares as of September 10, 2026, is reported to be 3,316,803 shares. This information may impact the company's market capitalization and is significant for investors watching share dilution and funding activities.
- : SEC 8-K (7.01): On September 9, 2026, Intelligent Bio Solutions Inc. announced the submission of its 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for regulatory clearance of its Intelligent Fingerprinting Drug Screening System, specifically designed for the detection of the opiate codeine. This strategic move aims to expand the company's product offerings in the drug testing market, facilitating compliance with health regulations. The press release detailing this submission is attached as Exhibit 99.1 to the filing, highlighting important advancements in their product line and potential market impact.
- : Intelligent Bio Solutions announces a private placement, securing approximately $5 million from a single existing institutional investor, under Nasdaq rules.
- : SEC 8-K (7.01): On September 1, 2026, Intelligent Bio Solutions Inc. announced the results of its latest Method Comparison Study for its Intelligent Fingerprinting Drug Screening System, specifically focusing on its ability to detect the opiate codeine. This press release aims to inform shareholders and the public about the advancements in their drug screening technology. The study results are critical for the company’s strategic positioning in the drug testing market, potentially impacting future sales and partnerships. A copy of the press release is included as Exhibit 99.1 in the Current Report.
- : SEC 8-K (1.01): On August 31, 2026, Intelligent Bio Solutions Inc. entered into a Securities Purchase Agreement with a single institutional investor to sell 2,036,659 shares of the Company’s common stock and associated warrants. This transaction included Series N-1 and Series N-2 warrants, which allow the investor to purchase the same number of shares. The sale is part of a private placement offering aimed at raising capital for the Company. The strategic implications include potential funding for future operations or projects, enhancing liquidity in the short term.
- : Intelligent Bio Solutions Secures Funding Through Private Placement
- : SEC 8-K (7.01): On August 28, 2026, Intelligent Bio Solutions Inc. provided a Regulation FD disclosure regarding a presentation made to investors about the company's business operations. The presentation is available for public access on the company's website. This disclosure is part of their commitment to transparency and keeping the stakeholders informed about their current operational status and strategic plans. The action reflects the company's efforts to engage with its investors amid ongoing business developments, highlighting its strategic significance.
- : SEC 8-K (7.01): On August 11, 2026, Intelligent Bio Solutions Inc. announced via a press release the completion of its multi-site Method Comparison Study for the Intelligent Fingerprinting Drug Screening System. This study is one of several that support the Company’s FDA 510(k) submission for U.S. market clearance specifically targeting the detection of the opiate codeine. The press release signifies an important development in the Company's regulatory process and potential market entry. This event highlights the Company’s commitment to enhancing drug screening technologies and can impact its market position significantly as it seeks FDA approval.
- : SEC 8-K (7.01): On August 5, 2026, Intelligent Bio Solutions Inc. announced the completion of its Usability Study for the Intelligent Fingerprinting Drug Screening System, as detailed in a press release (Exhibit 99.1). This event marks a significant development in the company's product offerings in the drug screening market. The completion of the study may have strategic implications for the company's future sales and customer adoption rates. The announcement was made in accordance with Regulation FD, ensuring that the information is disclosed publicly.
Intelligent Bio Solutions funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2026 | Post-IPO Equity | $5.0M |
| Aug 2026 | Funding Round | $2.0M |
| Jan 2026 | Post-IPO Equity | $10.0M |
| Aug 2025 | Seed | $3.8M |
| Mar 2024 | Venture | $10.1M |
Leadership
- Peter Passaris, Vice President
- Spiro Sakiris, Executive Officer
- Harry Simeonidis, Executive Officer
Verified email and direct lines for Intelligent Bio Solutions’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Intelligent Bio Solutions files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Intelligent Bio Solutions in the news
- A fingerprint drug test company will discuss its FDA submission Sept. 24 - Stock Titan (Sep 10, 2026)
- Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth - Moomoo (Aug 19, 2026)
- Intelligent Bio Solutions Submits FDA 510(k) for Drug Screening System to Detect Codeine - Quiver Quantitative (Sep 09, 2026)
- Intelligent Bio Solutions Inc. to Present at the Emerging Growth Conference on December 7, 2023 - GlobeNewswire (Nov 29, 2023)
- INBS: Intelligent Bio Solutions Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits (Oct 31, 2022)
- Intelligent Bio Solutions Inc. Reports Fiscal 2023 Second Quarter Financial Results and Operational Highlights - GlobeNewswire (Feb 14, 2023)
Companies similar to Intelligent Bio Solutions
- Medical Microinstruments · Health Care, Medical
- Encision · Health Care, Medical
- Picis Clinical Solutions · Health Care, Medical
- AKASA · Health Care, Medical
- Omnio · Health Care, Medical
About Intelligent Bio Solutions: questions and answers
What does Intelligent Bio Solutions do?
Intelligent Bio Solutions is on a mission to redefine the approach to testing and deliver pain-free, accessible solutions that drive transformative change and improve the quality of life.
Where is Intelligent Bio Solutions headquartered?
Intelligent Bio Solutions is headquartered in NEW YORK, New York.
How many employees does Intelligent Bio Solutions have?
Intelligent Bio Solutions has about 51 employees.
Has Intelligent Bio Solutions raised funding?
Yes. Fundz has recorded 5 funding events for Intelligent Bio Solutions. The most recent, Post-IPO Equity of $5.0M, was in Sep 2026.
Who leads Intelligent Bio Solutions?
Peter Passaris is a Vice President at Intelligent Bio Solutions.
What is the latest news on Intelligent Bio Solutions?
On Oct 13, 2026, SEC 8-K (7.01): The filing relates to a Regulation FD Disclosure by Intelligent Bio Solutions Inc, where they provided a presentation to investors on October 13, 2026. The presentation covers key aspects of the Company's business and operations, offering insights to stakeholders. Interested parties
Is Intelligent Bio Solutions a public company?
Yes. Intelligent Bio Solutions is publicly traded under the ticker INBS.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy